Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Phase II Study of Subcutaneous Melanotan Implant in Recurrent Polymorphous Light Eruption
2004-004074-93Phase 2Completed
- Sponsor
- EpiTan
- Start
- Jan 2005
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of Afamelanotide in polymorphic light eruption (PMLE) (2 arms), sponsored by EpiTan. Primary endpoints: Prevention or reduction of PMLE symptoms and Safety and tolerability. Started Jan 2005; status: completed.
02
Drugs
Afamelanotide
03
Conditions
polymorphic light eruption (PMLE)
Beyond the preview
Go deeper on 2004-004074-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004074-93.